Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Therapeutic Targets Beyond EGFR for Non-Small Cell Lung Cancer — Webinar Proceedings

Faculty

TARGET AUDIENCE
This activity is intended for medical oncologists, radiation oncologists, surgeons, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.

LEARNING OBJECTIVES

• Consider recently published data and available guideline recommendations to individualize first- and later-line therapy for patients with non-small cell lung cancer (NSCLC) harboring various targetable genetic abnormalities beyond EGFR.
• Review available clinical trial data evaluating the efficacy and safety of HER2-targeted tyrosine kinase inhibitors for patients with HER2-mutant NSCLC, and optimally identify individuals for whom treatment with this novel therapeutic strategy would be appropriate.
• Communicate the efficacy and safety of approved and investigational ALK inhibitors to appropriate candidates with localized and metastatic NSCLC.
• Convey the clinical relevance of a positive ROS1 mutation testing result to patients with NSCLC as appropriate, and appreciate available research findings with approved and emerging agents demonstrating efficacy in this disease.
• Assess available research evidence with approved RET inhibitors, and use this information to appropriately guide clinical care for patients with localized and metastatic NSCLC.
• Appreciate the incidence of c-Met overexpression in metastatic NSCLC, and recognize published clinical trial data with and the current role of novel antibody-drug conjugates in treatment for patients with high levels of this newly relevant biomarker.
• Understand the biology of KRAS G12C mutations, and evaluate available research findings with approved and investigational agents with documented activity in patients with these abnormalities.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
To receive credit for this activity, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better, and fill out the evaluation.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Heymach — Advisory Committees and Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BioNTech SE, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, GSK, Jazz Pharmaceuticals Inc, Johnson & Johnson, Lilly, Mirati Therapeutics Inc, ModeX Therapeutics, OncoHost, Ottimo Pharma, Pfizer Inc, Regeneron Pharmaceuticals Inc, Remunity Therapeutics, Spectrum Pharmaceuticals Inc, Synthekine, Takeda Pharmaceuticals USA Inc; Royalties and Licensing Fees: Spectrum Pharmaceuticals Inc. Dr Pérol — Advisory Committees: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, MSD, Novocure Inc, Nuvation Bio Inc, Pfizer Inc, PharmaMar, Sanofi, Takeda Pharmaceutical Company Limited; Consulting Agreements: Bristol Myers Squibb, Daiichi Sankyo Inc, MSD, Pfizer Inc; Data and Safety Monitoring Boards/Committees: PharmaMar; Speakers Bureaus: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Chugai Pharmaceutical Co Ltd, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, MSD, Novocure Inc, Pfizer Inc, Sanofi, Takeda Pharmaceutical Company Limited.

MODERATOR — Dr Love  is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals Inc, Genentech, a member of the Roche Group, and Nuvation Bio Inc.

Release date: August 2026
Expiration date: August 2027

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Barlesi F et al. Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): A randomised, open-label, phase 3 trial. Lancet 2025;406(10503):615-26. Abstract

Bazhenova L et al. Taletrectinib in TKI-naïve patients with ROS1+ NSCLC: Updated data from TRUST-I and TRUST-II. AACR 2026;Abstract CT300.

Besse B et al. Final efficacy and safety data from the phase I/II ARROW study of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer. J Clin Oncol 2026;44(13):1190-7. Abstract

Camidge DR et al. Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY trial. J Clin Oncol 2024;42(25):3000-11. Abstract

Cho BC et al. Repotrectinib in patients with ROS1 fusion-positive (ROS1+) NSCLC: Long-term follow-up from the phase 1/2 TRIDENT-1 trial. World Conference on Lung Cancer 2025;Abstract MA02.03.

Desilets A et al. Targeting ROS1 rearrangements in non-small cell lung cancer: Current insights and future directions. Cancer 2025;131(Suppl 1):e35784. Abstract

Drilon AE et al. Pivotal ARROS-1 efficacy and safety data: Zidesamtinib in TKI pre-treated patients with advanced/metastatic ROS1+ NSCLC. World Conference on Lung Cancer 2025;Abstract PL02.15.

Drilon AE et al. Repotrectinib in ROS1 fusion–positive non–small-cell lung cancer. N Engl J Med 2024;390(2):118-31. Abstract

Dziadziuszko R et al. Updated results from the phase III ALINA study of adjuvant alectinib vs chemotherapy (chemo) in patients (pts) with early-stage ALK+ non-small cell lung cancer (NSCLC). ESMO 2025;Abstract 1787MO.

Gautschi O et al. Selpercatinib in RET fusion-positive non-small cell lung cancer: Final safety and efficacy, including overall survival, from the LIBRETTO-001 phase I/II trial. J Clin Oncol 2025;43(15):1758-64. Abstract

Girard N et al. Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein–overexpressing nonsquamous EGFR wildtype advanced NSCLC: Updated analysis of the LUMINOSITY trial. European Lung Cancer Congress 2025;Abstract 18P.

Goldman JW et al. Event-free survival with adjuvant selpercatinib in stage IB-IIIA RET fusion-positive NSCLC: Primary results of the phase 3 LIBRETTO-432 trial. ASCO 2026;Abstract LBA3.

Heymach JV et al. First-line zongertinib in advanced HER2-mutant non-small-cell lung cancer. N Engl J Med 2026;394(17):1675-84. Abstract

Heymach JV et al. Zongertinib in treatment-naïve patients with HER2-mutant NSCLC, including those with active brain metastases: Beamion LUNG-1. European Lung Cancer Congress 2026;Abstract 6MO.

Heymach JV et al. Zongertinib in previously treated HER2-mutant non-small-cell lung cancer. N Engl J Med 2025;392(23):2321-33. Abstract

Jänne PA et al. Final analysis results and patient-reported outcomes from DESTINY-Lung02 — A dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic NSCLC. J Thorac Oncol 2025;20(12):1814-28. Abstract

Johnson ML et al. Efficacy and safety of 1L olomorasib plus pembrolizumab in KRAS G12C-mutant NSCLC: Results from LOXO-RAS-20001 and SUNRAY-01. World Conference on Lung Cancer 2025;Abstract MA02.06.

Krebs MG et al. Updated efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC. ESMO 2024;Abstract 1290P.

Le X et al. Sevabertinib (BAY 2927088) in advanced HER2-mutant non-small cell lung cancer (NSCLC): Results from the SOHO-01 study. ESMO 2025;Abstract LBA75.

Lin JJ et al. ALKOVE-1: Efficacy and safety of neladalkib in patients with advanced ALK+ NSCLC. ASCO 2026;Abstract 8503.

Liu G et al. Taletrectinib in TKI-pretreated patients with ROS1+ non-small cell lung cancer: Updated data from TRUST-I and TRUST-II. AACR 2026;Abstract CT244.

Loong HH et al. SOHO-01: Updated safety and efficacy of sevabertinib in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC). ASCO 2026;Abstract 8622.

Mok T et al. Lorlatinib vs crizotinib as first-line treatment for advanced ALK+ non-small cell lung cancer: 7-year update from the phase 3 CROWN study. ASCO 2026;Abstract 8502.

Negrao MV et al. Efficacy and safety of 1L olomorasib + chemoimmunotherapy in KRAS G12C-mutant NSCLC: Results from LOXO-RAS-20001 and SUNRAY-01. World Conference on Lung Cancer 2025;Abstract OA08.02.

Pérol M et al. Taletrectinib in ROS1+ non-small cell lung cancer: TRUST. J Clin Oncol 2025;43(16):1920-9. Abstract

Peters S et al. Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: Final overall survival analysis of the phase III ALEX study. Ann Oncol 2026;37(1):92-103. Abstract

Peters S et al. Entrectinib in ROS1-positive advanced non-small cell lung cancer: The phase 2/3 BFAST trial. Nat Med 2024;30(7):1923-32. Abstract

Planchard D et al. Trastuzumab deruxtecan in patients with HER2-overexpressing NSCLC: Results from part 1 of the open-label, multicenter, phase 1b DESTINY-Lung03 trial. J Thorac Oncol 2026;21(5):103541. Abstract

Popat S et al. Efficacy and safety of pralsetinib as first-line treatment of RET fusion-positive advanced or metastatic non–small cell lung cancer (NSCLC): The phase 3 AcceleRET-Lung study. ASCO 2026;Abstract 8504.

Ruiter G et al. Zongertinib in patients with previously treated HER2-mutant NSCLC and brain metastases at baseline: Beamion LUNG-1. World Conference on Lung Cancer 2025;Abstract PT2.12.03.

Sacher AG et al. Single-agent divarasib in patients with KRAS G12C-positive non-small cell lung cancer: Long-term follow-up of a phase I study. J Clin Oncol 2025;43(30):3249-53. Abstract

Shaw A et al. Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study. Ann Oncol 2026;[Online ahead of print]. Abstract

Skoulidis F et al. First-line (1L) divarasib plus pembrolizumab (pembro) in advanced or metastatic KRASG12C+ non-small cell lung cancer (NSCLC): Results from the Krascendo-170 study. ASCO 2026;Abstract 8510.

Wu YL et al. Selpercatinib in early-stage RET fusion–positive non–small-cell lung cancer. N Engl J Med 2026;[Online ahead of print]. Abstract